Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
| Brand name | RAMIPRIL |
| Generic name | RAMIPRIL |
| Active ingredient(s) | RAMIPRIL |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, MD |
| NDC | 68180-590-09 |
| Full product label | Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | Product was distributed to 30 wholesalers/distributors who may have further distributed the product nationwide. |
| Quantity | 146,322 bottles |
| Recall initiated | 2024-10-23 |
| Report date | 2024-11-27 |
| Recall completed | 2026-01-05 |
| Recall number | D-0053-2025 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Baltimore MD United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗